These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Expression of FANCD2 in sporadic breast cancer and clinicopathological analysis. Zhang B; Chen R; Lu J; Shi Q; Zhang X; Chen J J Huazhong Univ Sci Technolog Med Sci; 2010 Jun; 30(3):322-5. PubMed ID: 20556575 [TBL] [Abstract][Full Text] [Related]
63. Loss of BRCA1 expression in sporadic male breast carcinoma. Sun X; Gong Y; Rao MS; Badve S Breast Cancer Res Treat; 2002 Jan; 71(1):1-7. PubMed ID: 11859870 [TBL] [Abstract][Full Text] [Related]
64. Galectin-3 expression in human breast carcinoma: correlation with cancer histologic grade. Idikio H Int J Oncol; 1998 Jun; 12(6):1287-90. PubMed ID: 9592187 [TBL] [Abstract][Full Text] [Related]
65. Subcellular localization of BRCA1 protein in sporadic breast carcinoma with or without allelic loss of BRCA1 gene. Bernard-Gallon DJ; De Latour MP; Rio PG; Penault-Llorca FM; Favy DA; Hizel C; Chassagne J; Bignon YJ Int J Oncol; 1999 Apr; 14(4):653-61. PubMed ID: 10087311 [TBL] [Abstract][Full Text] [Related]
66. Expression of Plakophilins (PKP1, PKP2, and PKP3) in breast cancers. Demirag GG; Sullu Y; Yucel I Med Oncol; 2012 Sep; 29(3):1518-22. PubMed ID: 21947748 [TBL] [Abstract][Full Text] [Related]
67. Immunohistochemical analysis of BRCA1 expression in normal human buccal cells. Reece MT; Lane MA; Byrne TJ; Adams LA; Podgaysky AP; Cohn GM Oncol Rep; 1998; 5(5):1071-6. PubMed ID: 9683810 [TBL] [Abstract][Full Text] [Related]
68. An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion of non-familial breast cancers. Taylor J; Lymboura M; Pace PE; A'hern RP; Desai AJ; Shousha S; Coombes RC; Ali S Int J Cancer; 1998 Aug; 79(4):334-42. PubMed ID: 9699523 [TBL] [Abstract][Full Text] [Related]
69. Toponostics of invasive ductal breast carcinoma: combination of spatial protein expression imaging and quantitative proteome signature analysis. Röwer C; Ziems B; Radtke A; Schmitt O; Reimer T; Koy C; Thiesen HJ; Gerber B; Glocker MO Int J Clin Exp Pathol; 2011 Mar; 4(5):454-67. PubMed ID: 21738817 [TBL] [Abstract][Full Text] [Related]
70. BRCA1 immunohistochemistry assay: can it play a role in assessing sporadic early-onset breast cancer? Roehe AV; Boff AL; Damin A Breast J; 2012 Sep; 18(5):500-1. PubMed ID: 22897714 [No Abstract] [Full Text] [Related]
71. Cell membrane and cytoplasmic immunoreactivity of MIB-1 in invasive breast carcinoma. Ortiz-Rey JA; Peteiro A; Fernández-Costas A; Gómez de María C; Antón I Appl Immunohistochem Mol Morphol; 2009 Dec; 17(6):563-4. PubMed ID: 19620841 [No Abstract] [Full Text] [Related]
72. Validation of the BRCA1 antibody MS110 and the utility of BRCA1 as a patient selection biomarker in immunohistochemical analysis of breast and ovarian tumours. Milner R; Wombwell H; Eckersley S; Barnes D; Warwicker J; Van Dorp E; Rowlinson R; Dearden S; Hughes G; Harbron C; Wellings B; Hodgson D; Womack C; Gray N; Lau A; O'Connor MJ; Marsden C; Kvist AJ Virchows Arch; 2013 Mar; 462(3):269-79. PubMed ID: 23354597 [TBL] [Abstract][Full Text] [Related]
73. Immunohistochemical and proteomic evaluation of nuclear ubiquitous casein and cyclin-dependent kinases substrate in invasive ductal carcinoma of the breast. Ziółkowski P; Gamian E; Osiecka B; Zougman A; Wiśniewski JR J Biomed Biotechnol; 2009; 2009():919645. PubMed ID: 20069058 [TBL] [Abstract][Full Text] [Related]
74. Localization of BRCA1 protein in human breast cancer cells. Chambon M; Nirdé P; Gleizes M; Roger P; Vignon F Breast Cancer Res Treat; 2003 May; 79(1):107-19. PubMed ID: 12779087 [TBL] [Abstract][Full Text] [Related]
75. Immunohistochemical analysis of BRCA1 and acetyl-histone H3 in squamous cell carcinoma of the mobile tongue. Fonsêca TC; Abrantes TC; Fernandes PV; de Andrade BAB; Cabral MG; Romañach MJ; Agostini M; Abrahão AC Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Sep; 132(3):320-326. PubMed ID: 34030994 [TBL] [Abstract][Full Text] [Related]
76. Analysis of BRCA1 Gene Rearrangements in Breast Carcinomas by RT-PCR and ER, PR, HER2NEU Status by IHC and HPE Correlation. Prakhya S; Prakash G J Clin Diagn Res; 2012 Dec; 6(10):1663-8. PubMed ID: 23373023 [TBL] [Abstract][Full Text] [Related]
77. BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas. Garg K; Levine DA; Olvera N; Dao F; Bisogna M; Secord AA; Berchuck A; Cerami E; Schultz N; Soslow RA Am J Surg Pathol; 2013 Jan; 37(1):138-46. PubMed ID: 23232854 [TBL] [Abstract][Full Text] [Related]
78. The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer. Meisel JL; Hyman DM; Garg K; Zhou Q; Dao F; Bisogna M; Gao J; Schultz ND; Grisham RN; Phillips M; Iasonos A; Kauff ND; Levine DA; Soslow RA; Spriggs DR Ann Oncol; 2014 Dec; 25(12):2372-2378. PubMed ID: 25281711 [TBL] [Abstract][Full Text] [Related]
79. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459 [TBL] [Abstract][Full Text] [Related]
80. Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study. Hussein IA; Ahmed ST; Hameedi AD; Naji RZ; Alharbawi L; Alkhaytt M; Pity IS Asian Pac J Cancer Prev; 2020 Apr; 21(4):1025-1029. PubMed ID: 32334465 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]